Aprocitentan
Aprocitentan is a pharmaceutical drug that acts as a dual endothelin receptor antagonist. It is primarily used in the treatment of hypertension and other cardiovascular conditions. Aprocitentan works by blocking the action of endothelin, a potent vasoconstrictor, on its receptors, thereby helping to relax blood vessels and lower blood pressure.
Mechanism of Action
Aprocitentan targets both the endothelin receptor type A (ETA) and endothelin receptor type B (ETB). By inhibiting these receptors, aprocitentan prevents endothelin-1 (ET-1) from exerting its vasoconstrictive effects. This dual antagonism results in vasodilation, reduced vascular resistance, and ultimately, a decrease in blood pressure.
Clinical Uses
Aprocitentan is primarily indicated for the management of hypertension, particularly in patients who are resistant to conventional antihypertensive therapies. It may also be used in the treatment of other cardiovascular diseases where endothelin plays a significant role.
Pharmacokinetics
The pharmacokinetic profile of aprocitentan includes its absorption, distribution, metabolism, and excretion. Aprocitentan is well-absorbed after oral administration, with peak plasma concentrations typically reached within a few hours. It is metabolized primarily in the liver and excreted via the kidneys.
Side Effects
Common side effects of aprocitentan include headache, dizziness, and nasopharyngitis. More serious adverse effects may include edema, hypotension, and liver enzyme elevations. Patients should be monitored regularly for these potential side effects.
Contraindications
Aprocitentan is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with severe hepatic or renal impairment.
Research and Development
Aprocitentan is currently undergoing various clinical trials to further evaluate its efficacy and safety profile. Ongoing research aims to expand its therapeutic applications and optimize its use in clinical practice.
See Also
References
External Links
-
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD